在PI-RADS 3患者的前列腺MRI上定位PSMA PET-CT所示PSMA高摄取病灶
本研究纳入30例PI-RADS 3患者共38个病灶,将PSMA PET-CT图像融合至前列腺MRI,按PRIMARY评分对PI-RADS 3病灶分类。PSMA阳性(PRIMARY评分≥3)的PI-RADS 3病灶靶向活检csPCa比例为81.8%,PSMA阴性者为25.0%(P<0.001),敏感度和特异度分别为81.8%和75.0%。
要点
- PSMA阳性(PRIMARY评分≥3)的PI-RADS 3病灶靶向活检csPCa比例为81.8%,PSMA阴性者为25.0%(P<0.001)。
- 38个PI-RADS 3病灶中22个为PSMA阳性,其中18个(81.8%)靶向活检为csPCa;16个PSMA阴性病灶中4个(25.0%)为csPCa。
- 30例患者中12例(40.0%)存在16个不一致PSMA高摄取病灶,其中5例(41.7%)的不一致病灶PRIMARY评分高于PI-RADS 3病灶,该5例中4例(80%)系统活检GS高于靶向活检。
核心结论
- 病灶水平分析显示,PSMA阳性的PI-RADS 3病灶靶向活检csPCa概率高于PSMA阴性PI-RADS 3病灶;PRIMARY评分高于PI-RADS 3病灶的不一致PSMA高摄取病灶常代表MRI初检未识别的另一更具侵袭性病灶。
研究设计与样本
- 研究纳入2021至2023年间无临床显著前列腺癌(csPCa:Gleason评分[GS]3+4或更高)病史、前列腺MRI示PI-RADS 3、接受MRI/US融合靶向活检及系统活检、随后行PSMA PET-CT的患者;共30例患者(平均年龄67岁)38个PI-RADS 3病灶,将PSMA PET-CT图像融合至前列腺MRI,按PRIMARY评分对PI-RADS 3病灶分类,采用Fisher精确检验比较PSMA阳性与阴性PI-RADS 3病灶靶向活检csPCa比例,P<0.05为差异有统计学意义。
关键影像表现/征象
- 30例患者中29例有csPCa,1例为GS 6。
- 38个PI-RADS 3病灶中22个为PSMA阳性(PRIMARY评分≥3),16个为PSMA阴性(PRIMARY评分1或2)。
- 30例患者中12例(40.0%)存在16个不一致PSMA高摄取(PRIMARY评分≥2)病灶,10例有10个位于PI-RADS 3病灶外的不一致PSMA阳性病灶。
- 12例中5例(41.7%)的不一致PSMA高摄取病灶PRIMARY评分高于PI-RADS 3病灶。
- 该5例中4例(80%)系统活检GS高于靶向活检。
诊断标准与关键数值
- PSMA阳性定义为PI-RADS 3病灶PRIMARY评分≥3,PSMA阴性定义为PRIMARY评分1或2。
- PSMA阳性PI-RADS 3病灶靶向活检csPCa比例为18/22(81.8%),PSMA阴性者为4/16(25.0%)(P<0.001)。
- 靶向活检存在csPCa的敏感度为81.8%,特异度为75.0%。
临床应用与阅片要点
- 可将PSMA PET-CT图像融合至前列腺MRI,按PRIMARY评分对PI-RADS 3病灶进行分类。
- 应识别位于PI-RADS 3病灶外、PRIMARY评分更高的不一致PSMA高摄取病灶,因其常代表MRI初检未识别的另一更具侵袭性病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To localize PSMA-avid lesions identified by PSMA PET-CT on separately performed prostate MRI and evaluate imaging findings on fused PET-CT/MRI.
METHODS: Patients without prior history of clinically significant prostate cancer (csPCa: Gleason score [GS] 3 + 4 or higher) who had (1) PI-RADS 3 on prostate MRI between 2021 and 2023, (2) MRI/US fusion targeted biopsy for PI-RADS 3 lesion(s) and systemic biopsy, and (3) subsequent PSMA PET-CT were identified. PSMA PET-CT images were fused onto prostate MRI. PI-RADS 3 lesions were categorized by PRIMARY score. Discordant PSMA-avid lesions with PRIMARY scores 2-5 outside of PI-RADS 3 lesions were identified. Fisher's exact test was used to compare the proportion of csPCa on targeted biopsy between PSMA-positive (PRIMARY score 3 or more) and PSMA-negative (PRIMARY score 1 or 2) PI-RADS 3 lesions. P < 0.05 was considered statistically significant.
RESULTS: 30 patients (mean age 67 years) with 38 PI-RADS 3 lesions were identified. 29 patients had csPCa, and one patient had GS 6. 22 PI-RADS 3 lesions were PSMA-positive (PRIMARY score 3 or more), of which 18 (81.8%) were csPCa on targeted biopsy; 16 PI-RADS 3 lesions were PSMA-negative, of which 4 (25.0%) were csPCa on targeted biopsy (p < 0.001). Sensitivity and specificity for the presence of csPCa on targeted biopsy was 81.8% and 75.0%. Out of 30 patients, 12 (40.0%) had 16 discordant PSMA-avid (PRIMARY score 2 or more) lesions and 10 patients had 10 discordant PSMA-positive lesions outside PI-RADS 3 lesions In 5 of those 12 (41.7%), discordant PSMA-avid lesions had higher PRIMARY score than PI-RADS 3 lesions. In 4 of those 5 (80%), systemic biopsy showed higher GS than targeted biopsy.
CONCLUSION: Lesion-level analysis showed PSMA-positive PI-RADS 3 lesions had higher probability of csPCa than PSMA-negative PI-RADS 3 lesions. Discordant PSMA-avid lesions with higher PRIMARY score than that of PI-RADS 3 lesions often represented another more aggressive focus not initially identified on MRI.
引用
- Takahashi H, Nakai H, Ballman KV, et al. Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3. Abdom Radiol (NY). 2025. PMID: 40459597. doi:10.1007/s00261-025-05018-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。